ASX:RCERecce Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Recce Pharmaceuticals Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$0.48 -0.01 (-2.06 %) (As of 05/12/2020) Add Compare Share Today's RangeA$0.45Now: A$0.48▼A$0.5050-Day RangeA$0.23MA: A$0.37▼A$0.4952-Week RangeA$0.20Now: A$0.48▼A$0.60Volume630,087 shsAverage VolumeN/AMarket Capitalization$64.40 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsEarningsInsider TradesHeadlines Recce Pharmaceuticals Ltd, a biotechnology company, researches and develops antibiotic drugs in Australia. The company focuses on the development of RECCE 327 that helps to address the problem of antibiotic resistant superbugs. It also develops drugs for the treatment of stomach ulcers and diarrhea. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Recce Pharmaceuticals. Previous Next 2.6 Community Rank Outperform VotesRecce Pharmaceuticals has received 19 “outperform” votes. (Add your “outperform” vote.)Underperform VotesRecce Pharmaceuticals has received 18 “underperform” votes. (Add your “underperform” vote.)Community SentimentRecce Pharmaceuticals has received 51.35% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Recce Pharmaceuticals and other stocks. Vote “Outperform” if you believe RCE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RCE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldRecce Pharmaceuticals does not currently pay a dividend.Dividend GrowthRecce Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Recce Pharmaceuticals insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Recce Pharmaceuticals is -16.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Recce Pharmaceuticals is -16.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRecce Pharmaceuticals has a P/B Ratio of 13.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.52 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Drug Manufacturers - Major Sub-IndustryN/A SectorMedical Current SymbolASX:RCE Previous Symbol CUSIPN/A CIKN/A Webwww.recce.com.au Phone61 2 8075 4585Debt Debt-to-Equity Ratio3.36 Current Ratio8.00 Quick Ratio7.91Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.07 million Price / Sales60.09 Cash FlowA$0.04 per share Price / Cash Flow13.57 Book ValueA$0.04 per share Price / Book13.57Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares135,572,000Market Cap$64.40 million Next Earnings DateN/A OptionableNot Optionable Receive RCE News and Ratings via Email Sign-up to receive the latest news and ratings for RCE and its competitors with MarketBeat's FREE daily newsletter. Recce Pharmaceuticals (ASX:RCE) Frequently Asked Questions How has Recce Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Recce Pharmaceuticals' stock was trading at A$0.33 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, RCE stock has increased by 46.2% and is now trading at A$0.48. View which stocks have been most impacted by Coronavirus. How were Recce Pharmaceuticals' earnings last quarter? Recce Pharmaceuticals Ltd (ASX:RCE) issued its earnings results on Wednesday, February, 27th. The company reported ($0.01) EPS for the quarter. View Recce Pharmaceuticals' earnings history. Has Recce Pharmaceuticals been receiving favorable news coverage? Press coverage about RCE stock has been trending very positive recently, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Recce Pharmaceuticals earned a news sentiment score of 4.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View the latest news aboutRecce Pharmaceuticals. Who are some of Recce Pharmaceuticals' key competitors? Some companies that are related to Recce Pharmaceuticals include BEXIMCO PHARMAC/S GDR REGS (BXP), Eco Animal Health Group (EAH), Allergy Therapeutics (AGY), Trilogy International Partners (TRL), Futura Medical (FUM), NanoViricides (NNVC), Vita Life Sciences (VLS), Pharmaxis (PXS), Avivagen (VIV), Antisense Therapeutics (ANP), China Pharma (CPHI), Sareum (SAR), Patrys (PAB), Cathay International (CTI) and N4 Pharma (N4P). View all competitors. What other stocks do shareholders of Recce Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Recce Pharmaceuticals investors own include FlexiGroup (FXL), ASE Technology (ASX), IMMUTEP LTD/S (IMMP), Mavenir Systems (MVNR), Micron Technology (MU), Seres Therapeutics (MCRB), Ilika (IKA), Turtle Beach (HEAR), Applied Optoelectronics (AAOI) and First Graphene (FGR). Who are Recce Pharmaceuticals' key executives? Recce Pharmaceuticals' management team includes the following people: Dr. Graham John Hamilton Melrose BSc(Hons), Ph.D., MBA, FRACI, CChem, FAICD, Exec. Chairman & Chief Research Officer (Age 85)Mr. James Hamilton-Bray Graham, Exec. Director and Exec. Director of Marketing & Bus. Devel.Ms. Michele Dilizia, Exec. Director and Exec. Director of Regulatory Affairs & MicrobiologyDr. Justin Ward, Principal Quality ChemistMr. Justin Reynolds, Chief Financial Officer What is Recce Pharmaceuticals' stock symbol? Recce Pharmaceuticals trades on the ASX under the ticker symbol "RCE." What is Recce Pharmaceuticals' stock price today? One share of RCE stock can currently be purchased for approximately A$0.48. How big of a company is Recce Pharmaceuticals? Recce Pharmaceuticals has a market capitalization of $64.40 million and generates $1.07 million in revenue each year. What is Recce Pharmaceuticals' official website? The official website for Recce Pharmaceuticals is www.recce.com.au. How can I contact Recce Pharmaceuticals? The company can be reached via phone at 61 2 8075 4585. This page was last updated on 5/25/2020 by MarketBeat.com Staff
